{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:09:32Z","timestamp":1793297372236,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#545891, #1126090"],"award-info":[{"award-number":["#545891, #1126090"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Aims<\/jats:title>\n<jats:p>We report on motivations for crystal methamphetamine-opioid co-use\/co-injection through narratives of people who inject drugs during a period of increased crystal methamphetamine use reporting in Australia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Fourteen in-depth interviews were undertaken with selected participants (12 male, 2 female) from the Melbourne Injecting Drug User Cohort Study, including those in and out of opioid substitution therapy (OST).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The main motivations for co-use reported by participants were as follows: (1) that heroin could be used to reduce the negative side effects of heavy crystal methamphetamine use, particularly during the \u2018comedown\u2019 phase; (2) that small quantities of crystal methamphetamine used with heroin could prolong the intoxication effect of heroin, and hence the time before opioid withdrawal; (3) that co-injection of crystal methamphetamine and heroin produced a more desirable intoxication effect than using either substance on its own and; (4) that crystal methamphetamine provided a substitute \u2018high\u2019 for heroin after commencing OST treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Co-use of methamphetamine and opioids has been used by people who inject drugs to facilitate intoxication, sometimes as the result of ineffective opioid substitution therapy (OST) treatment and perceived lack of pleasure after stabilisation on OST treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12954-020-00360-9","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T22:18:37Z","timestamp":1582841917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Motivations for crystal methamphetamine-opioid co-injection\/co-use amongst community-recruited people who inject drugs: a qualitative study"],"prefix":"10.1186","volume":"17","author":[{"given":"Anna","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dietze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-5379","authenticated-orcid":false,"given":"Peter","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"issue":"1","key":"360_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1360-0443.2003.00236.x","volume":"98","author":"F Leri","year":"2003","unstructured":"Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2003;98(1):7\u201322.","journal-title":"Addiction."},{"key":"360_CR2","unstructured":"Peacock A, Gibbs D, Sutherland R, Uporova J, Karlsson A, Bruno R, et al. Australian Drug Trends 2018. Key Fundings from the National Illicit Drug Reporting System (IDRS) Interviews [Internet]. Sydney, National Drug and Alcohol Research Centre, UNSW Australia; 2018. Available from: https:\/\/ndarc.med.unsw.edu.au\/resource\/australian-drug-trends-2018-key-findings-national-illicit-drug-reporting-system-idrs."},{"issue":"6","key":"360_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1360-0443.2003.00376.x","volume":"98","author":"PO Coffin","year":"2003","unstructured":"Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction. 2003;98(6):739\u201347.","journal-title":"Addiction."},{"issue":"5","key":"360_CR4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.15288\/jsad.2016.77.774","volume":"77","author":"MC Meacham","year":"2016","unstructured":"Meacham MC, Strathdee SA, Rangel G, Armenta RF, Gaines TL, Garfein RS. Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico. J Stud Alcohol Drugs. 2016;77(5):774\u201381.","journal-title":"J Stud Alcohol Drugs."},{"issue":"2","key":"360_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1037\/1064-1297.8.2.176","volume":"8","author":"KK Downey","year":"2000","unstructured":"Downey KK, Helmus TC, Schuster CR. Treatment of heroin-dependent poly-drug abusers with contingency management and buprenorphine maintenance. Exp Clin Psychopharmacol. 2000;8(2):176.","journal-title":"Exp Clin Psychopharmacol."},{"key":"360_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drugpo.2017.07.009","volume":"49","author":"L Wang","year":"2017","unstructured":"Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;49:32\u201340.","journal-title":"Int J Drug Policy."},{"issue":"3","key":"360_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/BF02287318","volume":"30","author":"G Bovasso","year":"2003","unstructured":"Bovasso G, Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J Behav Heal Serv Res. 2003;30(3):290\u2013303.","journal-title":"J Behav Heal Serv Res."},{"issue":"1","key":"360_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1521-0391.2009.00003.x","volume":"19","author":"LE Sullivan","year":"2010","unstructured":"Sullivan LE, Moore BA, O\u2019Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, et al. The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine\/naloxone for the treatment of opioid dependence. Am J Addict. 2010;19(1):53\u20138.","journal-title":"Am J Addict."},{"issue":"2016","key":"360_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugpo.2016.06.001","volume":"36","author":"J Chalmers","year":"2016","unstructured":"Chalmers J, Lancaster K, Hughes C. The stigmatisation of \u2018ice\u2019 and under-reporting of meth\/amphetamine use in general population surveys: A case study from Australia. Int J Drug Policy. 2016;36(2016):15\u201324.","journal-title":"Int J Drug Policy."},{"issue":"4","key":"360_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/inm.12155","volume":"24","author":"K Usher","year":"2015","unstructured":"Usher K, Clough A, Woods C, Robertson J. Is there an ice epidemic in Australia? Int J Ment Health Nurs. 2015;24(4):283\u20135.","journal-title":"Int J Ment Health Nurs."},{"key":"#cr-split#-360_CR11.1","unstructured":"The Australian Institute of Health and Welfare. National drug strategy household survey detailed report 2013 [Internet]. Drug statistics series no. 28. Cat. no. PHE 183. Canberra, Australia"},{"key":"#cr-split#-360_CR11.2","unstructured":"2014. Available from: http:\/\/www.aihw.gov.au\/alcohol-and-other-drugs\/ndshs\/%5Cnfiles\/97\/ Australian Institute of Health and Welfare - 2014 - National Drug Strategy Household Survey detailed r.pdf%5Cnhttp:\/\/meteor.aihw.gov.au\/content\/index.phtml\/itemId\/558897%5Cnhttp:\/\/www.aihw."},{"issue":"1","key":"360_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/add.12740","volume":"110","author":"N Scott","year":"2015","unstructured":"Scott N, Caulkins JP, Ritter A, Quinn C, Dietze P. High-frequency drug purity and price series as tools for explaining drug trends and harms in Victoria, Australia. Addiction. 2015;110(1):120\u20138.","journal-title":"Addiction."},{"issue":"2","key":"360_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/dar.12426","volume":"36","author":"L Degenhardt","year":"2016","unstructured":"Degenhardt L, Sara G, McKetin R, Roxburgh A, Dobbins T, Farrell M, et al. Crystalline methamphetamine use and methamphetamine-related harms in Australia. Drug Alcohol Rev. 2016;36(2):160\u201370.","journal-title":"Drug Alcohol Rev."},{"issue":"4","key":"360_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0376-8716(84)90005-X","volume":"13","author":"DE Hunt","year":"1984","unstructured":"Hunt DE, Lipton DS, Goldsmith D, Strug D. Street pharmacology: uses of cocaine and heroin in the treatment of addiction. Drug Alcohol Depend. 1984;13(4):375\u201387.","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"360_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3109\/10826088509056357","volume":"20","author":"DL Strug","year":"1985","unstructured":"Strug DL, Hunt DE, Goldsmith DS, Lipton DS, Spunt B. Patterns of cocaine use among methadone clients. Int J Addict. 1985;20(8):1163\u201375.","journal-title":"Int J Addict."},{"issue":"3","key":"360_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1521-0391.1993.tb00428.x","volume":"2","author":"SM Stine","year":"1993","unstructured":"Stine SM, Satel S, Kosten T. Cocaine precipitation of patient-identified opiate withdrawal. Am J Addict. 1993;2(3):255\u20138.","journal-title":"Am J Addict."},{"issue":"4","key":"360_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1300\/J069v15n04_01","volume":"15","author":"B Frank","year":"1996","unstructured":"Frank B, Galea J. Cocaine trends and other drug trends in New York City, 1986-1994. J Addict Dis. 1996;15(4):1\u201312.","journal-title":"J Addict Dis."},{"issue":"3","key":"360_CR18","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00005053-198803000-00006","volume":"176","author":"TR Kosten","year":"1988","unstructured":"Kosten TR, Rounsaville BJ, Kleber HD. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J Nerv Ment Dis. 1988;176(3):176\u201381.","journal-title":"J Nerv Ment Dis."},{"issue":"3","key":"360_CR19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/archpsyc.1987.01800150101012","volume":"44","author":"TR Kosten","year":"1987","unstructured":"Kosten TR, Rounsaville BJ, Kleber HD. A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? Arch Gen Psychiatry. 1987;44(3):281\u20134.","journal-title":"Arch Gen Psychiatry."},{"key":"360_CR20","unstructured":"Bloor M. A user\u2019s guide to contrasting theories of HIV-related risk behaviour. Sociol Heal Illn Monogr Ser. 1995:19\u201330."},{"issue":"2","key":"360_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0955-3959(02)00007-5","volume":"13","author":"T Rhodes","year":"2002","unstructured":"Rhodes T. The \u2018risk environment\u2019: a framework for understanding and reducing drug-related harm. Int J Drug Policy. 2002;13(2):85\u201394.","journal-title":"Int J Drug Policy."},{"issue":"7","key":"360_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.socscimed.2004.01.029","volume":"59","author":"D Moore","year":"2004","unstructured":"Moore D. Governing street-based injecting drug users: a critique of heroin overdose prevention in Australia. Soc Sci Med. 2004;59(7):1547\u201357.","journal-title":"Soc Sci Med."},{"issue":"3","key":"360_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drugalcdep.2006.02.005","volume":"84","author":"P Dietze","year":"2006","unstructured":"Dietze P, Jolley D, Fry CL, Bammer G, Moore D. When is a little knowledge dangerous? Circumstances of recent heroin overdose and links to knowledge of overdose risk factors. Drug Alcohol Depend. 2006;84(3):223\u201330.","journal-title":"Drug Alcohol Depend."},{"key":"360_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.drugpo.2017.10.001","volume":"49","author":"F Dennis","year":"2017","unstructured":"Dennis F, Farrugia A. Materialising drugged pleasures: practice, politics, care. Int J Drug Policy. 2017;49:86\u201391.","journal-title":"Int J Drug Policy."},{"key":"360_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1477-7517-10-11","volume":"10","author":"D Horyniak","year":"2013","unstructured":"Horyniak D, Higgs P, Jenkinson R, Degenhardt L, Stoov\u00e9 M, Kerr T, et al. Establishing the Melbourne Injection Drug Cohort Study. Harm Reduct J. 2013;10:11.","journal-title":"Harm Reduct J."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-020-00360-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-020-00360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:35:21Z","timestamp":1614299721000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00360-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["360"],"URL":"https:\/\/doi.org\/10.1186\/s12954-020-00360-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"2 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Monash University Human Research Ethics Committee for this study (Project #CF16\/889\u20142016000457). All participants signed informed consent prior to the interview and were reimbursed A$40 for their time and travel costs.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants were informed that publication in peer reviewed journals may be one outcome of their involvement in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PH has received funding from Gilead Science and Abbvie for investigator-initiated research unrelated to this study. PD has received an investigator-driven grant from Gilead Sciences for unrelated work on hepatitis C and an untied educational grant from Reckitt Benckiser for unrelated work on the introduction of buprenorphine-naloxone into Australia.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}